Appendiceal neuroendocrine tumours (aNET) account for 50%–77% of all appendiceal neoplasms and are mostly identified incidentally following appendicectomy for acute appendicitis or after a laparotomy performed for unrelated reasons. In the great majority, aNET are low grade (>80% grade 1 (G1)) and very rarely, if ever, are associated with a secretory syndrome.
This post is part of my ENETS Guideline series and supplements my Spotlight series article which can be found by clicking here.
| Q1 – What is the current incidence of aNET (G1-3)? |
| Q2 – Which are the pathological parameters that need to be provided for further decision-making? |
| Q3 – How common are LN and distant metastases and carcinoid syndrome (CS) in appendiceal NET? Is LN status an acceptable surrogate of OS? |
| Q4 – Is there any indication for biochemical and/or imaging modalities to be utilised for tumour staging following appendicectomy? |
| Q5 – Is there any indication for biochemical and/or imaging modalities to be utilised for tumour staging following appendicectomy? |
| Q6 – When completion oncological surgery is recommended, is RHC always required or could ileocaecal resection be sufficient, and what is the impact of these |
| Q7 – Is there any need for adjuvant therapy in patients with aNET without distant metastases? |
| Q8 – How should advanced disease be managed? |
| Q9 – What is the recommended follow-up protocol after RHC in patients with or without LN+ ? How is follow-up in aNET justified? |
Now read the reference material below including where applicable to the 9 questions above.
Click on the blue link below to read the discussion and the recommendations for each of those questions.
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
When I was diagnosed, I didn’t even feel ill. It was therefore a bit of a shock being told I had metastatic cancer, advanced enough to
I was assessing performance of the awareness period in November 2025 on Facebook and was astonished to find the size of my reach on that
Here is the monthly summary of November 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis, discovery of the
Discover more from Ronny Allan – Living with Neuroendocrine Cancer Subscribe to get the latest posts sent to your email. Type your email… Subscribe
Bone metastases in Neuroendocrine Tumours (NET) Many of you will know that I am a stage IV small intestine NET and I have one bone
What is Radioligand Therapy? When you browse the internet, you may see the term “Radioligand Therapy (RLT)” and wondered what it was. There’s a simple
D Day I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea
USA – Prevalence of Neuroendocrine Neoplasms (NENs) breaches the Orphan Disease threshold for the first time (officially) The latest US SEER figures confirm that staggering
Reframing Neuroendocrine Neoplasms: Beyond “Rare” Neuroendocrine neoplasms (NENs) have outgrown the “rare disease” label. e.g. Across the U.S., UK, and Australia, they now rank among
Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc
Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!
£4.00
Subscribe to get the latest posts sent to your email.
